Data support the integration of ultrasound-guided methods along with arthroscopy into clinical trial protocols requiring sequential joint sampling for subsequent histological and molecular analysis.
For patients with rheumatoid arthritis, abatacept conferred a greater reduction in CVD risk compared with TNF inihibitors.
Maternal RA exposure in utero may increase the risk for certain chronic conditions, including RA, thyroid disease, and epilepsy.
Investigators sought to determine which characteristics are predictive of remission induction and subsequent loss of remission in patients with moderately active RA.
Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
They similarities and differences of anti-TNF drug function in RA and SpA are discussed in an expert interview.
Researchers assessed the rates of composite cardiovascular events in people with RA using NSAIDs to treat musculoskeletal pain.
Presence of thrombocytopenia at hospital admission may serve as an important prognostic marker for predicting in-hospital mortality for patients with RHD.
RA-specific factors may predispose individuals to developing COPD independent of smoking.
Findings from 2 studies examine the role that weight loss, obesity, and overweight play in disease activity, remission, and mortality in RA.
The safety of leflunomide use for rheumatoid arthritis during pregnancy was examined in a prospective study.
The protective effects of disease-modifying antirheumatic drugs in dementia was evaluated in a retrospective cohort study.
There are important differences in TNFis for specific clinical conditions that recent research has made more apparent.
Although recent pharmacologic advances have improved disease progression and prognosis in RA, a number of patients experience joint stiffness.
A randomized study sough to evaluate whether methotrexate monotherapy can safely be started before treatment optimization with a tumor necrosis factor inhibitor in patients with early, active RA.
A prospective, observational study sought to evaluate and characterize the nature of rheumatic disorders associated with immune checkpoint inhibitors.
In patients with RA who have achieved remission or low disease activity (LDA), discontinuation of biologic disease-modifying antirheumatic drugs is associated with an increased risk for losing remission or LDA and radiographic progression.
In patients with rheumatic diseases, the incidence of pneumocystis pneumonia was reduced with primary prophylaxis with trimethoprim/sulfamethoxazole.
Megan Clowse, MD, MPH, discusses 2 studies that examine reproductive health concerns in women with inflammatory rheumatic diseases.
Tocilizumab treatment for 2 years was shown to reduce levels of bone loss in patients with ACPA-positive RA.
Early treatment of undifferentiated arthritis may delay progression to rheumatoid arthritis.
Using biologics to treat rheumatoid arthritis patients does not appear to increase the risk of a second malignancy in individuals with history of cancer.
In patients with rheumatoid arthritis being treated with a biologic disease-modifying antirheumatic drug with and without denosumab, serious and opportunistic infections are uncommon.
The Fear Assessment in Inflammatory Rheumatic diseases questionnaire may be useful to evaluate the levels of fear and psychological distress in patients with rheumatoid arthritis and axial spondyloarthritis.
Patients with rheumatoid arthritis may be at increased risk for prosthetic joint infection and death after total knee or hip arthroplasty, compared with patients with osteoarthritis.
Patients with rheumatoid arthritis appear to be at increased risk for chronic obstructive pulmonary disease.
Topical NSAIDs are associated with a lower risk for cardiovascular events compared with oral NSAIDs in patients with rheumatoid arthritis.
The Nurses' Health Study was used to assess the risk of COPD and asthma in women with rheumatoid arthritis.
Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.
A future risk for Guillain-Barré syndrome is correlated with early life immune disorders.
Rheumatology Advisor Articles
- Raynaud Phenomenon, Migraine Linked to aPS/PT Antibodies in Primary Antiphospholipid Syndrome
- Case Study: A Syncopal Episode During a Camping Trip
- Then and Now: The Crisis of Physician Suicides
- Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA
- Aspirin Similar to Rivaroxaban for VTE Prophylaxis After Hip, Knee Arthroplasty
- FDA Advises Recall: Limbrel May Be Linked to Drug-Induced Liver Injury
- Allopurinol Use May Lower Risk for Peripheral Arterial Disease
- Managing Treatment Nonadherence in Rheumatic Diseases
- Optimal Fibromyalgia Management Includes Individualized, Multimodal Therapy
- Risk for COPD, Asthma Among Women With Rheumatoid Arthritis: Nurses' Health Study
- Ocular Complications of Gout: The Spectrum of Urate Crystal Deposition
- Digital Medicine Innovations Expand Access to Rural, Low-Income Communities
- Elevated Serum Uric Acid Levels May Increase Risk for Dementia in Older Adults
- Implications of the Regulatory Accountability Act on Public Health
- Synovial Joint Biopsy Techniques: Arthroscopy vs Ultrasound-Guided Methods